Drug intelligence / Profile preview

CTX4000

Development stage: Preclinical
Lead developer: Celosia Therapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies

Overview

CTX4000 is a gene therapy program under development by Celosia Therapeutics for the treatment of epilepsy syndromes, specifically Dravet Syndrome. The therapy targets Mitogen-activated protein kinase 12 (MAPK12), also known as P38gamma kinase. As a genetic medicine, CTX4000 aims to deliver disease-modifying gene sequences to modulate neuronal pathways involved in severe, drug-resistant childhood epilepsies. The program is currently in the discovery stage of development.

Targets

MAPK12 (Mitogen-activated protein kinase 12)

Beyond the preview

Go deeper on CTX4000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX4000.

Explore the full profile